AN2 Therapeutics, Inc. (ANTX)

NASDAQ: ANTX · Delayed Price · USD
12.74
-5.69 (-30.87%)
At close: May 17, 2022 4:00 PM
12.98
0.24 (1.88%)
After-hours:May 17, 2022 4:51 PM EDT
Market Cap247.19M
Revenue (ttm)n/a
Net Income (ttm)-34.72M
Shares Out19.40M
EPS (ttm)-1.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume153,156
Open18.79
Previous Close18.43
Day's Range12.42 - 20.29
52-Week Range12.46 - 23.58
Betan/a
AnalystsBuy
Price Target25.16 (+97.5%)
Earnings Daten/a

About ANTX

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Epetraborole has broad spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Its novel mechanism of action is enabled by boron chemistry, our core technology approach. W...

IndustryHealth Care
IPO DateMar 25, 2022
CEOEric Easom
Employees22
Stock ExchangeNASDAQ
Ticker SymbolANTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is 25.16, which is an increase of 97.49% from the latest price.

Price Target
$25.16
(97.49% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious inf...

1 week ago - GlobeNewsWire

AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high ...

1 week ago - Business Wire

RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15

AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million.  The Company announced IPO plans earl...

1 month ago - Benzinga

AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering

MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious disea...

1 month ago - GlobeNewsWire